US-based CRO, Health Decisions, hopes to raise the efficacy standards for complex studies and help companies get products to market faster by establishing an international network of CROs.
CRO Health Decisions hopes to raise the efficacy standards for complex studies and help companies get products to market faster by establishing an international network of CROs.
"It's no surprise that, as development moves overseas, disparate systems and gaps in information inevitably drive up costs and prolong development timelines," Rick Farris, Health Decisions Chief Operations Officer, explained in a press statement. "This network will serve as an incredibly valuable resource to combat inefficiency in global clinical trials."
In the statement, Health Decisions claims that its proprietary Agile approach to clinical research forms "a set of best practices that consistently cuts trial timelines, increases transparency and delivers vastly improved results". The CRO has identified like-minded CROs worldwide and will be offering training, certification and partnership opportunities. Farris said: "Regardless of what they call it - Agile clinical development or otherwise - if they're comfortable with adaptive techniques in both design and operations, and pride themselves on relentless efficiency in clinical research, we want to talk to them."
The company's training programme, which will comprise Flash-based online courses, will primarily focus on adaptive operations that are easy to implement for all types of trials once the proper infrastructure is in place.
Farris added: "Our goal is to identify like-minded organizations worldwide that embrace the idea that we, as an industry, can run better global studies."
A webcast from Health Decisions can be viewed here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.